New brain cancer drug shows promise in early trial
NCT ID NCT06806228
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tests whether adding a drug called S-Gboxin to standard treatment can help people with glioblastoma, a fast-growing brain cancer. The drug works by cutting off the energy supply to cancer cells. Ten patients with recurrent or progressive disease will receive S-Gboxin alongside standard therapy. Researchers will use brain scans to measure changes in tumor metabolism and size, and track survival and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
S-Gboxin, a drug that targets energy production in cancer cells
What this could lead to
If it works, this could point toward a new way to treat glioblastoma by blocking the energy supply of tumor cells.
What could go wrong
This is a very early, small pilot study with only 10 participants. The drug may not work or could cause side effects. The trial is currently suspended.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Kazakh Institute of Oncology and Radiology
Almaty, 490 078, Kazakhstan
-
National Cancer Institute
Kyiv, 33/43, Ukraine
-
Tbilisi Cancer Centre
Tbilisi, 0198, Georgia